The therapeutic landscape for autoimmune diseases has been revolutionized by Argenx's VYVGART, which stands as the inaugural FcRn inhibitor to receive regulatory approval. This breakthrough therapy has achieved significant clinical success in treating generalized myasthenia gravis (gMG) and continues to demonstrate promising results across additional therapeutic areas, including immune...
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek